Nearly 60% of US adults qualify for at least one novel cardiovascular, kidney, or metabolic drug — most often a GLP-1 receptor agonist — with many eligible for more than one class of drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results